Itai Hecht - Medivie Therapeutic CEO
| MDVI Stock | ILA 35.50 2.00 5.97% |
CEO
Mr. Itai Hecht serves as Chief Executive Officer of a Subsidiary of Medivie Therapeutic Ltd effective February 20, 2018. The Subsidiary is called HiPharma Ltd. His work experience includes the role of Vice Manager at Sewage Treatment PlantPalgey Sharon . He holds a Bachelors degree in Geography and Environmental Studies from Haifa University. Additionally, he holds a High National Diploma in Water and Soil Studies from Rupin College. since 2018.
| Age | 37 |
| Tenure | 6 years |
| Phone | 44 8708 200 096 |
| Web | http://www.medivie.com |
Medivie Therapeutic Management Efficiency
The company has return on total asset (ROA) of (1.0886) % which means that it has lost $1.0886 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5598) %, meaning that it generated substantial loss on money invested by shareholders. Medivie Therapeutic's management efficiency ratios could be used to measure how well Medivie Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 6 records | CEO Age | ||
| Arie Amir | Hiron Trade Investments Industr | 77 | |
| Igal Atrakchi | Aura Investments | 48 | |
| Yoel Azaria | Oron Group Investments | 55 | |
| Dan Rozner | Hiron Trade Investments Industr | 81 | |
| Gil Azaria | Oron Group Investments | 55 | |
| Roy Gadish | Adgar Investments and | 61 | |
Management Performance
| Return On Equity | -1.56 | |||
| Return On Asset | -1.09 |
Medivie Therapeutic Leadership Team
Elected by the shareholders, the Medivie Therapeutic's board of directors comprises two types of representatives: Medivie Therapeutic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medivie. The board's role is to monitor Medivie Therapeutic's management team and ensure that shareholders' interests are well served. Medivie Therapeutic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medivie Therapeutic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Omri Wolf, Internal Auditor | ||
| Irit BenAmi, External Director | ||
| Itai Hecht, Chief Executive Officer of the Company’s Subsidiary | ||
| Uri BenOr, Vice President - Finance | ||
| Yigal Fatran, External Director | ||
| Uri Or, Chief Officer | ||
| Pr MBBS, Chief Scientist | ||
| Eyal Paauw, Independent Director | ||
| Yigal Hevroni, Chairman of the Board | ||
| Menachem Cohen, Chief Executive Officer, Director |
Medivie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medivie Therapeutic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.56 | |||
| Return On Asset | -1.09 | |||
| Operating Margin | (24.81) % | |||
| Current Valuation | 47.6 M | |||
| Shares Outstanding | 2.88 M | |||
| Shares Owned By Insiders | 72.29 % | |||
| Price To Book | 10.59 X | |||
| Price To Sales | 71.11 X | |||
| Revenue | 491 K | |||
| Gross Profit | (603 K) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Medivie Stock
Medivie Therapeutic financial ratios help investors to determine whether Medivie Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medivie with respect to the benefits of owning Medivie Therapeutic security.